Eutilex Co Ltd
263050
Company Profile
Business description
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.
Contact
Daeryung Technotown 17
Suite 1401
Gasan Digital 1-ro 25
Geumcheon-gu
Seoul08594
KORT: +82 234027310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
120
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
Aussie property manager lifts earnings expectations despite interest rate uncertainty.
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,904.70 | 26.20 | 0.30% |
| CAC 40 | 8,173.11 | 85.15 | -1.03% |
| DAX 40 | 25,184.89 | 204.21 | -0.80% |
| Dow JONES (US) | 50,461.68 | 118.02 | -0.23% |
| FTSE 100 | 10,491.39 | 25.13 | 0.24% |
| HKSE | 25,381.51 | 217.94 | -0.85% |
| NASDAQ | 26,656.18 | 312.21 | 1.19% |
| Nikkei 225 | 65,633.61 | 637.52 | 0.98% |
| NZX 50 Index | 13,207.71 | 137.97 | 1.06% |
| S&P 500 | 7,519.12 | 45.65 | 0.61% |
| S&P/ASX 200 | 8,674.80 | 22.60 | 0.26% |
| SSE Composite Index | 4,099.23 | 46.14 | -1.11% |